An accelerated path to approval 

By integrating information from a well-understood drug agent, a large dataset in patients with the active molecule tramiprosate, novel genetic markers and insights into the pathology of Alzheimer’s disease (AD), we have created ALZ-801, an optimized prodrug of tramiprosate.  ALZ-801 is one of the few drug candidates in advanced stages of clinical testing in AD, a pill with a favorable safety profile and the potential to modify an underlying cause of the disease.

About ALZ-801

16Jun, 2016

Alzheon to Present at the 2016 JMP Securities Life Sciences Conference

June 16th, 2016|

FRAMINGHAM, Mass., June 16, 2016 – Alzheon Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that Martin Tolar, M.D., [...]

11Mar, 2016

Alzheon Announces Efficacy Analyses of Prior Tramiprosate Phase 3 Studies   Showing Clinically Meaningful Benefits on Key Clinical Endpoints in Alzheimer’s Disease Patients with APOE4 Genotype

March 11th, 2016|

Results Support Advancement of ALZ‐801 into Pivotal Clinical Studies in APOE4/4 Homozygous Subjects with Mild to Moderate Alzheimer’s Disease Data Presented at the 14th Annual International Athens/Springfield Symposium on Advances in Alzheimer Therapies Conference [...]

Load More Posts

In the news

26Jan, 2016

Alzheon Highlighted as One of the “Top 20 Life Science Startups to Watch in the U.S.”

January 26th, 2016|

Alzheon is focused on developing treatments for patients with Alzheimer’s disease and other neurological and psychiatric disorders. The company’s lead clinical product candidate, ALZ-801, is an oral inhibitor of amyloid aggregation and neurotoxicity—hallmarks of [...]

8Apr, 2015

Alzheon Gets $10M to Take Castoff Alzheimer’s Drug Into Pivotal Test

April 8th, 2015|

Run by a veteran of drug R&D for Alzheimer’s disease, Alzheon is betting that a smart trial design and a little chemistry work could turn a failed drug for the memory-robbing disorder [...]

Load More Posts